First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial

已完结 10 由北大西大发布于 2026/10/29 10:35:29

DOI:10.1016/s2213-2600(23)00431-9
作者：Hua Zhong, Shengjie Sun, Jianhua Chen, Ziping Wang, Yanqiu Zhao, Guojun Zhang, Gongyan Chen, Ming Zhou, Jianying Zhou, Yingying Du, Lin Wu, Zhi Xu, Xiaodong Mei, Weidong Zhang, Jingdong He, Jiuwei Cui
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：BackgroundPenpulimab is a novel programmed death (PD)-1 inhibitor. This study aimed to establish the efficacy and safety of first line penpulimab plus chemotherapy for advanced squamous non-

应助信息

19小时前

vwan

8a2c2d2dd34211f1aa73208810ba6e4f.pdf 已采纳

19小时前

Book学术机器人

2026/10/29 10:35:29 未找到该文献，机器人已退出，请等待人工下载

2026/10/29 10:35:29 Book学术AI机器人收到请求，开始寻找文献

2026/10/29 10:35:29 已向机器人发送请求

19小时前

北大西大发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库[China Guideline for Diagnosis and Treatment of Incisional Hernia (2018 edition)].